Another study showed that the MR antagonist, spironolactone, promoted white adipose tissue browning and hepatic glucose transporter type 4 expression, suggesting that MR signaling mediates diet-induced hepatic steatosis, the dysregulation of adipose tissue browning, and systemic and tissue insulin resistance [33]. The gene discussed is NR3C2; the disease is fatty liver disease.